AB-101 is under clinical development by Artiva Biotherapeutics and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase II drugs for B-Cell Non-Hodgkin Lymphoma have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AB-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AB-101 is under development for the treatment of solid tumor and B-cell non-Hodgkin lymphoma, relapsed or refractory chronic lymphocytic leukemia. The therapeutic candidate is an allogeneic universal NK cell therapy for use in combination with monoclonal antibody. It is being developed based on AlloNK platform and it is administered by parenteral route.
Artiva Biotherapeutics overview
Artiva Biotherapeutics is a biotechnology company developing allogeneic natural killer (NK) cell therapies to treat hematologic cancers or solid tumors. It is investigating AB-101, an allogeneic NK cell therapy used for the treatment of B-cell malignancies; AB-201, a CAR-NK (chimeric antigen receptor modified natural killer) cell therapy targeting HER2 positive solid tumors; and AB-202 against CD19 positive B-cell malignancies. Artiva Biotherapeutics utilizes its proprietary CAR (chimeric antigen receptor) platform to improve the therapeutic activity and tumor targeting capability of NK cells. The company was funded by 5AM Ventures, VenBio Partners LLC, RA Capital Management LP and Medivate Healthcare Investments Asia. Artiva Biotherapeutics is headquartered in San Diego, California, the US.
For a complete picture of AB-101’s drug-specific PTSR and LoA scores, buy the report here.